Metraipolis › archive › dc_501bfc284c1e

Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies — Europe PMC PMID:41425090

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41425090
DOI
10.3389/fcell.2025.1719978
License (as archived)
solo-consultazione
Archived
2026-11-07T22:14:02.720Z
SHA-256 of the archived text
abac4402c739bafd4ff906a9ab96748ae34ff93aa5b224a3f57f731dff427062
Stable URL of this page
https://metraipolis.com/documento/dc_501bfc284c1e

How to cite

Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies — Europe PMC PMID:41425090 — Europe PMC (en), https://europepmc.org/article/MED/41425090 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_501bfc284c1e (Metraipolis archive dc_501bfc284c1e, sha256 abac4402c739bafd4ff906a9ab96748ae34ff93aa5b224a3f57f731dff427062)
BibTeX
@misc{dc501bfc284c1e,
  title = {Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies — Europe PMC PMID:41425090},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41425090},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_501bfc284c1e; sha256 abac4402c739bafd4ff906a9ab96748ae34ff93aa5b224a3f57f731dff427062},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41425090. Agents can read the archived copy with the MCP tool read_document.